['idiopathic pulmonary fibrosis']
['glpg1690 600 mg qd', 'placebo qd']

        Inclusion Criteria:

          1. Subjects able and willing to sign the Institutional Review Board (IRB)/Independent
             Ethics Committee (IEC) approved Informed Consent Form (ICF)

          2. Male or female subjects of non-child-bearing potential aged ≥ 40 years

          3. Subjects with a chest HRCT performed within 12 months prior to screening

          4. Subjects with IPF diagnosed by a multidisciplinary team

          5. Subjects with: a. forced vital capacity (FVC) ≥50% predicted of normal AND b.
             Diffusing capacity for the lungs for carbon monoxide (DLCO) ≥ 30% predicted of normal
             corrected for hemoglobin

          6. Subjects with a forced expiratory volume in 1 second (FEV1)/FVC (Tiffeneau-Pinelli
             index) ratio ≥ 0.70 (based on pre-bronchodilator spirometry

          7. Subjects on stable supportive care

          8. Subjects in stable condition

        Exclusion Criteria:

          1. Subjects with know hypersensitivity to any of the study drug ingredients

          2. Subjects with a history of or current immunosuppressive condition

          3. Subjects with a history of malignancy within the past 5 years

          4. Subjects with clinically significant abnormalities on ECG

          5. Subjects with acute IPF exacerbation within 6 weeks prior to screening

          6. Subjects with a lower respiratory tract infection requiring antibiotics with 4 weeks
             prior to screening

          7. Smoking within 3 months pre-screening

          8. Interstitial lung disease

          9. History of lung volume reduction surgery or lung transplant

         10. Unstable cardiac or pulmonary disease other than IPF within 6 months prior to
             screening

         11. Subjects with abnormal liver function

         12. Subjects with abnormal renal function
      